Nitsche, Mirko

[["dc.bibliographiccitation.firstpage","643"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","International Journal of Radiation Biology"],["dc.bibliographiccitation.lastpage","657"],["dc.bibliographiccitation.volume","84"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Luecke, Eva-Maria"],["dc.contributor.author","Peters, Kerstin"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Schmidberger, Heinz"],["dc.contributor.author","Pradier, Olivier"],["dc.date.accessioned","2018-11-07T11:20:07Z"],["dc.date.available","2018-11-07T11:20:07Z"],["dc.date.issued","2008"],["dc.description.abstract","Purpose: Despite proven antitumor activity of gemcitabine in chemoradiotherapy of advanced head and neck cancer, many authors refer to severe acute and late local and haematological toxicity. Fludarabine does imply nearly the same mechanisms of action as gemcitabine, inhibiting various enzymes involved in DNA replication. This investigation focuses on the combined effect of either fludarabine or gemcitabine and radiation on human squamous carcinoma cell lines in vitro, providing data for future decisions on head and neck chemoradiotherapy regimen. Materials and methods: ZMK-1, A549, BW-225, GR-145, OH-65 and CaSki cell lines were incubated with either drug at defined schedules and irradiated at a single fraction dose of 2 Gy every 24 hours up to 8 Gy. Cytotoxic effects were measured by colony-forming assays, quantitative determination of apoptosis and isobologram analysis. Results: Incubation of fludarabine led to a radiosensitizing effect in the A549, CaSki and ZMK-1 cell lines and an additive effect in the BW-225, GR-145 and OH-65 cell lines. Treatment with gemcitabine only indicated significant radiosensitization in the CaSki cell line in combination with augmented resistance against gemcitabine application alone. Conclusions: Our results reveal a potential radiosensitizing effect of fludarabine and its possible application in chemoradiotherapy of advanced head and neck carcinoma and possibly other tumor entities."],["dc.identifier.doi","10.1080/09553000802241754"],["dc.identifier.isi","000258002000003"],["dc.identifier.pmid","18661380"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55460"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Informa Healthcare"],["dc.relation.issn","0955-3002"],["dc.title","The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines in vitro"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1067"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","International Journal of Radiation Oncology*Biology*Physics"],["dc.bibliographiccitation.lastpage","1074"],["dc.bibliographiccitation.volume","65"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Martin, Alexios"],["dc.contributor.author","Florez, Rodrigo"],["dc.contributor.author","Kahler, Elke"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Steiner, Wolfgang"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Pradier, Olivier"],["dc.date.accessioned","2018-11-07T09:32:05Z"],["dc.date.available","2018-11-07T09:32:05Z"],["dc.date.issued","2006"],["dc.description.abstract","Purpose: The aim of this study was to evaluate the efficacy of adjuvant radiotherapy after transoral laser microsurgery for advanced recurrent head-and-neck squamous cell carcinoma (HNSCC). Patients and Methods: Between 1988 and 2000, 37 patients with advanced local recurrences (23 local and 14 locoregional recurrences) of HNSCC without distant metastases were treated in curative intent with organ-preserving transoral laser microsurgery and adjuvant radiotherapy (before 1994 split-course radiotherapy with carboplatinum, after 1994 conventional radiotherapy). Initial therapy of the primary (8.1% oral cavity, 35.1% oropharynx, 13.5% hypopharynx, and 43.3% larynx) before relapse was organ-preserving transoral laser microsurgery without any adjuvant therapy. Results: After a median follow-up of 124 months, the 5-year overall survival rate was 21.3%, the loco-regional control rate 48.3%, respectively. In multivariate analysis, stage of original primary tumor (Stage I/II vs. Stage III/IV), and patient age (< 58 years vs. >= 58 years) showed statistically significant impact on prognosis. In laryngeal cancer, larynx preservation rate after treatment for recurrent tumor was 50% during follow-up. Conclusion: Our data show that organ-preserving transoral laser microsurgery followed by adjuvant radiotherapy is a curative option for patients who have advanced recurrence after transoral laser surgery and is an alternative to radical treatment. (c) 2006 Elsevier Inc."],["dc.identifier.doi","10.1016/j.ijrobp.2006.03.007"],["dc.identifier.isi","000238878800015"],["dc.identifier.pmid","16750331"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31668"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","0360-3016"],["dc.title","Long-term follow-up after transoral laser microsurgery and adjuvant radiotherapy for advanced recurrent squamous cell carcinoma of the head and neck"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]